NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/17/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,874.27 mln
Float55.10 mln
Earnings Date11/18/2026
Piotroski F-Score
4
/ 9
Borderline
1-Year Forecast
105
Transformational upside
Relative Strength
86
/ 100
Strongly outperforming
Debt / Equity
0.00
Debt-free
ROE
-18.33
Negative
Dividend Yield
0.00%
No dividend
Business Description
Structure Therapeutics is a clinical-stage pharmaceutical company focused on developing oral pill-based treatments for chronic conditions that currently lack good solutions, including obesity and lung disease. Its most advanced drug candidate, GSBR-1290, targets a key metabolic receptor and is currently being tested in two mid-stage clinical trials for obesity and related conditions. The company has several other drug programs in earlier stages of development, targeting a range of biological pathways involved in metabolism and tissue scarring. Founded in 2016 and based in South San Francisco, Structure Therapeutics operates across the United States and globally.
